Compare Panacea Biotech with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs AUROBINDO PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH AUROBINDO PHARMA PANACEA BIOTECH/
AUROBINDO PHARMA
 
P/E (TTM) x 12.4 14.3 86.8% View Chart
P/BV x 3.0 3.1 96.0% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PANACEA BIOTECH   AUROBINDO PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
AUROBINDO PHARMA
Mar-18
PANACEA BIOTECH/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs364809 45.0%   
Low Rs129504 25.6%   
Sales per share (Unadj.) Rs96.8281.1 34.4%  
Earnings per share (Unadj.) Rs-12.441.4 -30.0%  
Cash flow per share (Unadj.) Rs-2.950.9 -5.6%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs50.4199.4 25.3%  
Shares outstanding (eoy) m61.25585.88 10.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.52.3 109.1%   
Avg P/E ratio x-19.915.9 -125.2%  
P/CF ratio (eoy) x-86.412.9 -669.9%  
Price / Book Value ratio x4.93.3 148.6%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m15,101384,630 3.9%   
No. of employees `0002.517.3 14.2%   
Total wages/salary Rs m1,51621,308 7.1%   
Avg. sales/employee Rs Th2,401.99,500.7 25.3%   
Avg. wages/employee Rs Th614.21,229.4 50.0%   
Avg. net profit/employee Rs Th-307.91,397.9 -22.0%   
INCOME DATA
Net Sales Rs m5,928164,666 3.6%  
Other income Rs m821,020 8.1%   
Total revenues Rs m6,010165,686 3.6%   
Gross profit Rs m84537,718 2.2%  
Depreciation Rs m5855,580 10.5%   
Interest Rs m1,006777 129.4%   
Profit before tax Rs m-66432,380 -2.0%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m998,183 1.2%   
Profit after tax Rs m-76024,229 -3.1%  
Gross profit margin %14.322.9 62.3%  
Effective tax rate %-14.925.3 -58.8%   
Net profit margin %-12.814.7 -87.1%  
BALANCE SHEET DATA
Current assets Rs m5,603121,878 4.6%   
Current liabilities Rs m6,91086,806 8.0%   
Net working cap to sales %-22.021.3 -103.5%  
Current ratio x0.81.4 57.8%  
Inventory Days Days206130 158.5%  
Debtors Days Days8468 122.5%  
Net fixed assets Rs m9,94181,037 12.3%   
Share capital Rs m61586 10.5%   
"Free" reserves Rs m3,026116,218 2.6%   
Net worth Rs m3,087116,804 2.6%   
Long term debt Rs m5,7074,512 126.5%   
Total assets Rs m16,076211,052 7.6%  
Interest coverage x0.342.7 0.8%   
Debt to equity ratio x1.80 4,786.1%  
Sales to assets ratio x0.40.8 47.3%   
Return on assets %1.511.8 12.9%  
Return on equity %-24.620.7 -118.7%  
Return on capital %3.927.4 14.3%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60080,727 2.0%   
Fx outflow Rs m1,13134,700 3.3%   
Net fx Rs m46946,027 1.0%   
CASH FLOW
From Operations Rs m1,18019,548 6.0%  
From Investments Rs m553-19,570 -2.8%  
From Financial Activity Rs m-1,6448,642 -19.0%  
Net Cashflow Rs m908,922 1.0%  

Share Holding

Indian Promoters % 74.5 54.1 137.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 8.0 7.5%  
FIIs % 1.3 27.7 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.2 231.4%  
Shareholders   10,259 69,601 14.7%  
Pledged promoter(s) holding % 35.1 8.6 409.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Petrol and Diesel Prices, DHFL Saga, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended their trading session marginally higher yesterday. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 18, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - UNICHEM LAB COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS